Screener
Janux Therapeutics JANX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Assets | June 30,2026 / (unaudited) | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 3) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; authorized shares – 10,000,000 at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; authorized shares – 200,000,000 at June 30, 2026 and December 31, 2025; issued and outstanding shares – 61,077,980 and 60,384,283 at June 30, 2026 and December 31, 2025, respectively | 61 | 60 |
| Additional paid-in capital | 1,327,943 | 1,303,828 |
| Accumulated other comprehensive income (loss) | (2,305) | 4,316 |
| Accumulated deficit | (397,715) | (351,382) |
| Total stockholders’ equity | 927,984 | 956,822 |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's common stock?
- Janux Therapeutics (JANX) reported common stock of $61K in Q2 2026.
- How has Janux Therapeutics's common stock changed year-over-year?
- Janux Therapeutics's common stock increased by 3.4% year-over-year, from $59K to $61K.
- What is the long-term trend for Janux Therapeutics's common stock?
- Over 5 years (2020 to 2025), Janux Therapeutics's common stock has grown at a 126.8% compound annual growth rate (CAGR), from $1K to $60K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Janux Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude